Bayer's Roundup win clearly erases about $0.8 billion in verdicts. The market added $7.5 billion.

On Wednesday, 25 June 2026, the Supreme Court handed Bayer the legal victory it had chased for seven years. In Monsanto v. Durnell, the justices ruled 7-2 that a 1947 federal pesticide law blocks one specific kind of Roundup cancer lawsuit. Investors reacted as if the entire problem had been solved. Bayer's shares jumped about 17 percent in Frankfurt, the biggest single-day move since March 2003, rising as much as 17 percent intradayintradayPrice movement that happens within a single trading day, before the closing price is set. before trading was briefly halted for volatility. The US-listed shares, traded as American depositary receipts, ran hotter still, climbing into the low twenties; we anchor to the German ordinary shareordinary shareA company's main, locally listed stock, here, Bayer's shares traded in Frankfurt in euros, the cleanest read on the whole company's value., the cleanest read on the whole company.

A 17 percent move is not an abstraction. The day before the ruling, Bayer was worth about $44.2 billion. A 17 percent gain on that base adds about $7.5 billion of market value in a single session.

Built from the opinion, Bayer's own disclosures, and the analyst who sized the exposure before the ruling, our answer is that the decision clearly removes far less than the market priced. The clearest measure of what it touches is about $0.8 billion. The market added nearly ten times that. The rest is a bet on questions the Court did not decide, and we will be explicit about where that bet might be right.

The case turns on the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRAFIFRAThe Federal Insecticide, Fungicide, and Rodenticide Act, a 1947 US law under which the EPA approves pesticide labels, including what warnings they must carry.). Under it, the EPAEPAThe US Environmental Protection Agency, which regulates pesticides and has rated glyphosate 'not likely' to cause cancer. approves a pesticide's label, including required warnings. The EPA has long held that glyphosateglyphosateThe active weed-killing chemical in Roundup, which lawsuits allege can cause cancer., Roundup's active ingredient, is 'not likely' to cause cancer, so it never required a cancer warning.

John Durnell, a Missouri man who used Roundup for about two decades and developed non-Hodgkin lymphomanon-Hodgkin lymphomaA cancer of the lymph system that many Roundup plaintiffs say their exposure caused., sued on a failure-to-warn theory: that Monsanto should have put a cancer warning on the bottle anyway. A jury awarded him $1.25 million. The Court threw it out. Justice Brett Kavanaugh, writing for the majority, reasoned that because FIFRA bars states from demanding a label 'in addition to or different from' the federal one, a state jury cannot punish Monsanto for omitting a warning the EPA chose not to require. Think of it as a federal permission slip: if Washington signed off on the label, a state court cannot retroactively rule it wrong. In dissent, Justice Jackson, joined by Justice Gorsuch, warned that the majority 'misunderstands FIFRA's requirements' and 'ultimately leaves Durnell without a remedy for the significant harms he has suffered.'

Durnell preempts only failure-to-warn claims. The defense bar said so within hours. Crowell & Moring noted that design-defect, manufacturing-defect, and advertising claims, plus risks the EPA 'did not affirmatively consider,' may remain viable. Holland & Knight read the holding narrowly too: FIFRA preempts warning claims contrary to the EPA-approved label, but theories such as manufacturing defect, express warranty, and fraud not tied to label content can survive, and each one still has to be dismissed case by case, in state courts, where plaintiffs can re-plead the theories that were not preempted.

A win on the dominant theory is not a win on every theory. The ruling closes one door in a building with several.

Before the decision, Bloomberg Intelligence litigation analyst Holly Froum sized the existing verdicts directly exposed to the warning question at about $787 million, and said a Bayer win 'would eliminate plaintiffs' strongest claim.' Set that beside the $7.5 billion the market added the day of the ruling.

Two numbers, one trading day. The market added nearly ten dollars for every one the ruling clearly removes. This is the floor of what Durnell does, not a measured total, it counts verdicts that already exist, not the future filings the decision may deter. That distinction is the whole argument, and we take it seriously next.

It is not weak, and an honest desk has to state it. Bayer says the decision should dismiss the 'vast majority' of roughly 65,000 pending claims. If failure-to-warn underpins most of them, and the surviving theories are weak on contested science (the EPA rates glyphosate 'not likely' carcinogenic; the WHO's cancer agency, IARCIARCThe World Health Organization's International Agency for Research on Cancer, which classifies glyphosate as 'probably' carcinogenic, the opposite of the EPA's view., says 'probably'), then Durnell drains most of the litigation's expected valueexpected valueThe probability-weighted average outcome, here, the likely total cost of the lawsuits factoring in the odds of winning or losing each.. On that reading, the $787 million badly understates the effect, because it counts only crystallized verdicts and ignores every future suit the ruling now deters. Ignoring this would be propaganda. The gap between $0.8 billion and $7.5 billion is, in large part, the price of that deterrence, a number nobody can yet measure. But three facts cut hard against treating the rally as settled fact.

First, the surviving theories are the plaintiffs' next move, not a hypothetical. Claims get amended, not erased. The defense memos above concede that design-defect, negligence, and fraud theories survive Durnell and must be beaten one by one. A ruling that forces re-pleading is not the same as a ruling that ends the cases.

Second, Bayer is behaving like a company that still expects to pay. It is actively pursuing the $7.25 billion King v. Monsanto class settlementclass settlementA single deal that resolves a large group of similar lawsuits at once, often including future claimants who do not opt out., announced in February 2026, and its glyphosate-specific reserve rose into the win, not down.

A firm that believed Durnell had extinguished its liability would be releasing reserves and walking away from settlements, not raising the first and prosecuting the second. The reserve is management's own probability-weighted estimate of what this litigation costs, and it points the opposite way from the share price.

Third, this company has declared the end before. In June 2020 Bayer announced a roughly $10.9 billion 'comprehensive' Roundup settlement; another $4.5 billion followed in 2021, a further EUR 1.2 billion (about $1.37 billion) reserve top-up in August 2025, and now $7.25 billion in February 2026.

Roughly $10 to $11 billion has actually been paid out across the earlier tranches. Each deal was billed as the one that would draw a line under the problem; none did.

Where this pattern could break in Bayer's favor: Durnell is the first of these turning points carved by the nation's highest court rather than negotiated at a settlement table. A binding precedentprecedentA court ruling that lower courts must follow in later, similar cases, making it more durable than a one-off negotiated deal. that lower courts must follow is a different instrument from a voluntary deal, and it could deter new filings in a way no prior settlement managed. That is the honest upside. But it remains a forecast about future behavior, not a liability that has been struck from the books.

Step back and the full board makes the mismatch plain. Bayer is carrying about EUR 11.8 billion (roughly $13.5 billion) in glyphosate-related provisions and has already paid out some $10 to $11 billion. Against that mountain, the verdicts Durnell clearly erases are a sliver.

Strip away the noise and the disagreement reduces to one testable question. If Durnell truly drained the litigation, the evidence will be unmistakable within a few quarters: Bayer would release glyphosate reserves rather than build them, let the King settlement lapse rather than steer it through its fairness hearingfairness hearingA court session where a judge decides whether a proposed class settlement is fair before granting final approval., and watch new filings dry up. If instead the reserve holds or climbs, the settlement closes, and plaintiffs simply re-plead design-defect and fraud, then the market paid $7.5 billion for a door that shut while the building stayed open.

The ruling is real and the relief is rational. The size of the rally is the part still waiting for evidence.